Alice Ventures

novoGI Inc. specializes in the design and development of device-driven solutions for managing gastrointestinal (GI) diseases. The company offers innovative nitinol-based compression anastomosis devices that facilitate the natural reconnection of the intestine after resections, such as those performed in colon cancer treatments. This technology represents a significant advancement in gastrointestinal surgery, as it leverages biological healing processes to enhance patient outcomes. novoGI, originally founded in 1996 as NiTi Surgical Solutions, changed its name in June 2012. The company is headquartered in Atlanta, Georgia, with additional European operations in Paris and research, development, and manufacturing facilities in Netanya, Israel. Its product line includes FDA-cleared and CE-marked disposable tissue closure devices that are designed to support effective healing in patients undergoing colorectal procedures.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for central nervous system diseases, particularly acute ischemic stroke. Founded in 2000, the company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Its innovative treatment approach involves a miniature electrode implanted in the roof of the mouth through a minimally invasive procedure performed under local anesthesia. BrainsGate's key product is an ischemic stroke system that delivers targeted stimulation to the SPG, with the aim of improving outcomes for stroke patients. The company has conducted significant clinical trials, including a pivotal study with 300 participants that demonstrated the safety and efficacy of its treatment. Currently, BrainsGate is advancing the ImpACT-24b trial, a multinational randomized study assessing the treatment's effectiveness within a critical 24-hour window following stroke onset.

Tehuti Networks Ltd. is a fabless semiconductor company based in Herzliya, Israel, founded in 2003. The company specializes in the development of Ethernet network traffic accelerators and Ethernet controllers, focusing on enhancing performance while maintaining low power consumption. Tehuti's products are designed to support high-volume applications in enterprise data centers, IP video servers, and various server platforms, enabling the adoption of 10 Gigabit Ethernet technology. Their 10GbE controllers operate in a partial offload mode, facilitating easier integration and optimized performance for clients requiring multi-gigabit Ethernet connectivity. Tehuti Networks has received support from the Technion R&D Fund to advance its TCP/IP acceleration technology and has attracted investments from several venture capital firms.

Mazor Robotics, founded in 2001 and headquartered in Caesarea, Israel, specializes in developing, producing, and marketing medical devices for orthopedic and neurosurgical procedures. The company's primary focus is on surgical robotic-guidance systems that enhance precision and minimize invasiveness during complex surgeries. Their flagship products include the Mazor X and Renaissance systems, which are used extensively in spine surgeries such as fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. These systems aim to provide a safer surgical environment for patients, surgeons, and operating room staff by transforming traditional freehand procedures into highly accurate, state-of-the-art operations with better clinical outcomes.

Andritz Powerlase Ltd. specializes in the design and manufacture of high-power pulsed lasers tailored for industrial applications, particularly in materials processing. Established in 2000 and located in Crawley, United Kingdom, the company provides a range of laser technologies, including infrared, green, and ultraviolet lasers. These lasers are utilized for various functions such as surface polishing, rust removal, de-painting, laser annealing, and cleaning, as well as in the processing of composite materials. Andritz Powerlase serves diverse sectors, including automotive, aerospace, and defense, by delivering innovative solutions that enhance production efficiency and meet specific industry requirements. Formerly known as Powerlase Photonics Limited, the company adopted its current name in June 2017 and operates as a subsidiary of Andritz AG.

Intense Limited is a company based in Glasgow, United Kingdom, that specializes in the design, manufacture, and supply of single and multimode monolithic laser array products and high-power laser diodes. Established in 1999, Intense offers a range of products, including visible and infra-red laser diodes, laser diode bars, and individually addressable laser arrays. The company serves multiple sectors, including defense and security, medical, consumer and industrial applications, digital printing and imaging, and display technologies. Additionally, Intense provides foundry services such as front-end wafer processing, back-end assembly, engineering support, and product development, along with comprehensive design services for laser diodes, optics, electronics, and packaging. The company has a strategic partnership with IQE and operates manufacturing facilities in both the United Kingdom and the United States.

Ignios Ltd., an Oxford, UK-based developer of system-on-a-chip technologies.

Sagitta Ltd. is a technology-based equipment supplier for the fiber optics and semiconductor industries. A core holding of patented technologies in precision automation, machine vision and sub micron polishing has led to the introduction of multiple systems into these markets. The company has introduced the Gemini product series, a platform first in the fiber optics market to integrate the processes of polishing, cleaning and optical metrology on a single platform. Already a leader in failure analysis equipment for the semiconductor and media fields, Sagitta provides an award-winning suite of sample preparation tools used for cross sectional, SEM or TEM semiconductor inspection.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for central nervous system diseases, particularly acute ischemic stroke. Founded in 2000, the company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Its innovative treatment approach involves a miniature electrode implanted in the roof of the mouth through a minimally invasive procedure performed under local anesthesia. BrainsGate's key product is an ischemic stroke system that delivers targeted stimulation to the SPG, with the aim of improving outcomes for stroke patients. The company has conducted significant clinical trials, including a pivotal study with 300 participants that demonstrated the safety and efficacy of its treatment. Currently, BrainsGate is advancing the ImpACT-24b trial, a multinational randomized study assessing the treatment's effectiveness within a critical 24-hour window following stroke onset.

SerCoNet is a developer of Ethernet backbone networking solutions for home consumers & SOHOs (Small Office Home Office) over existing telephone wires.

Arakis Limited is a company dedicated to the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The firm specializes in researching cytokine and receptor-mediated mechanisms of disease, allowing it to identify and develop new clinical applications for established drugs and drug templates. By leveraging known medicines, Arakis aims to create performance-enhanced therapies, addressing unmet medical needs in its targeted therapeutic areas, which include inflammatory disease and pain management.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Arakis Limited is a company dedicated to the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The firm specializes in researching cytokine and receptor-mediated mechanisms of disease, allowing it to identify and develop new clinical applications for established drugs and drug templates. By leveraging known medicines, Arakis aims to create performance-enhanced therapies, addressing unmet medical needs in its targeted therapeutic areas, which include inflammatory disease and pain management.